Research programme: H1N1 influenza virus therapies -Sarepta Therapeutics/Defense Threat Reduction Agency

Drug Profile

Research programme: H1N1 influenza virus therapies -Sarepta Therapeutics/Defense Threat Reduction Agency

Alternative Names: Swine flu therapies - AVI/DTRA

Latest Information Update: 16 Jul 2012

Price : $50

At a glance

  • Originator AVI BioPharma
  • Developer Sarepta Therapeutics
  • Class Antisense oligonucleotides
  • Mechanism of Action Immunomodulators; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Influenza A virus H1N1 subtype

Most Recent Events

  • 12 Jul 2012 Preclinical development is ongoing in the US
  • 12 Jul 2012 AVI BioPharma is now called Sarepta Therapeutics
  • 15 Apr 2010 Preclinical trials in Influenza-A virus H1N1 subtype in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top